0      0

JL1119ES - JL1119ES: Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: sensitivity analysis of survival from the NAPOLI 3 trial

‐ Nov 2, 2023 2:00pm

Lead author: Z.A. Wainberg, MD

Presenter for JADPRO Live: Kathleen Sacharian, MSN, CRNP, AOCNP

Z.A. Wainberg, MD (1) , D. Melisi, MD (2), T. Macarulla, MD (3), R.A. Pazo Cid, MD (4), S.R. Chandana, MD (5), C. De La Fouchardière, MD (6), A. Dean, MD (7), I. Kiss, MD (8), W.J. Lee, MD, (9), T.O. Goetze, MD (10), E. Van Cutsem, MD (11), S. Paulson, MD (12), T. Bekaii-Saab, MD (13), S. Pant, MD (14), R. Hubner, MD (15), Z. Xiao, MD (16), H. Chen, PhD (16), F. Benzaghou, MD (16), E.M. O’Reilly, MD (17)

1) University of California, Los Angeles, CA, USA; 2) Investigational Cancer Therapeutics Clinical Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; 3) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; 4) Hospital Universitario Miguel Servet, Zaragoza, Spain; 5) Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA; 6) Centre Léon Bérard, Lyon, France; 7) St John of God Subiaco Hospital, Subiaco, WA, Australia; 8) Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czechia; 9) National Cancer Center, Goyang, Republic of Korea; 10) Krankenhaus Nordwest, Frankfurt, Germany; 11) University Hospitals Gasthuisberg Leuven and KULeuven, Leuven, Belgium; 12) Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA; 13) Mayo Clinic, Scottsdale, AZ, USA; 14) MD Anderson Cancer Center, Houston, TX, USA; 15) The Christie NHS Foundation Trust, Manchester, UK; 16I) psen, Cambridge, MA, USA; 17) Memorial Sloan Kettering Cancer Center, New York, NY, USA



You must be logged in and own this session in order to post comments.